New-ATE-Logo2019 (1)

 

Debunking Dogma:

Unique Capabilities of a CVDMO Providing Real

Speed and Affordability for Cell and Gene Therapy

Presenter:

08-14-2025-Vector-BioMed-ATE-Speaker-HS-Cropped
Andrew Worden 
Chief Technology Officer,
Vector BioMed 
 
 
Andrew began his career in the United States Army, and while serving at the Army’s Medical Research Institute of Infectious Diseases (USAMRIID), he supported the development of new Immunoassay and Real-Time PCR technologies to detect potential biological warfare agents. He received an undergraduate degree from George Washington University and later joined VIRxSYS where he worked for 7 years as part of the team first approved to initiate clinical trials of a first-in-class Lentiviral gene therapy product in humans.

During his time at VIRxSYS, Andrew developed improved methods for Autologous T-Cell manufacturing, where he focused on increasing process efficiency, reducing material costs, and identifying methods for improved post-thaw recovery of cryopreserved cell products. Following his time managing Cell Process Development, he worked for 5 years between Process Development roles at Wellstat Ophthalmics and Advanced Bioscience Laboratories where he focused on Polymer, Lipid, and Electroporation based delivery of DNA to various cell types to produce biologics including recombinant therapeutic proteins, virus-like particle-based vaccines, and viral vectors for gene therapy.

Andrew joined Lentigen Technology Inc. (a Miltenyi company) in 2015 as head of Process Development. He was responsible for developing the company’s first serum-free, suspension 200L Lentiviral vector manufacturing process as well as establishing scaled-down models for efficient production of large-scale comparable vector batches utilized in pre-clinical studies. He has extensive experience with multiple technologies to produce and purify BIV and HIV based Lentiviral vectors including variation of envelope pseudotypes. In addition to developing and optimizing production processes, Andrew oversaw the evaluation and implementation of new analytical technologies to improve characterization of Lentiviral vector and better understand the process related impurities. He has led Process Characterization for multiple products intended for commercialization and with over 20 years of Process and Analytical Development, he currently serves as the Chief Technology Officer of Vector BioMed.